| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT01210378 Details | 2019-02-15 Interventional | 2 | 47 | Nitroglycerin Carcinoma, Non-… Lung Neoplasms Non Small Cell … | Accrual stopped - | |||
| NCT01003418 Details | 2019-02-15 Interventional | 2 | 8 | Heptavalent Pne… Influenza, Huma… Influenza | The study was terminated prematurely for logistic reasons, not related to safety or efficacy of
the vaccine. - | |||
| NCT00917293 Details | 2019-02-15 Interventional | 2 | 53 | Pyridoxal Pyridoxal Phosp… Dyskinesias Tardive Dyskine… | modified formulation under investigation - | |||
| NCT03559387 Details | 2019-02-12 Interventional | 2 | 9 | Lenograstim Neutropenia Chemotherapy-in… | Study redesign - | |||
| NCT02588261 2015-002894-39 Details | 2019-02-12 Interventional | 3 | 530 | Erlotinib Hydro… Gefitinib Naquotinib Carcinoma, Non-… Lung Neoplasms Non-small Cell … | Following recommendation by SOLAR Study IDMC, Astellas closed enrollment in ASP8273 studies - | |||
| NCT01403246 Details | 2019-02-12 Interventional | 1/2 | 9 | Chlorambucil Lenalidomide Leukemia Leukemia, Lymph… Leukemia, Lymph… Chronic Lymphoc… | Slow patient enrollment and new molecules for chronic lymphoid leukemia, have importantly
reduced the interest of conducting the phase II of this study. - | |||
| NCT02346370 Details | 2019-02-08 Interventional | 1 | 16 | Docetaxel Carcinoma, Non-… Lung Neoplasms Non-small Cell … | Changing standard of care therapy regimen This study was discontinued early by the Sponsor during the Dose Escalation Period. | |||
| NCT01957644 2013-001290-24 Details | 2019-02-08 Interventional | 1 | 16 | Azacitidine Leukemia Leukemia, Myelo… Myelodysplastic… Preleukemia Syndrome | - The sponsor discontinued the development of volasertib on 25 Nov 2016 and this trial was discontinued on 16 Dec 2016 for non-clinical reasons. The number of patients enrolled in Part 2 of the study was too small for a meaningful analysis. | |||
| NCT02787798 Details | 2019-02-07 Interventional | 4 | 4 | Sacubitril and … Valsartan Heart Failure | Today Entresto treatment has marketing authorization and is available for all patients, that is
the reason why study was halted prematurely. - | |||
| NCT02438761 Details | 2019-02-06 Interventional | 2 | 10 | Gedatolisib Leukemia Leukemia, Myelo… Leukemia, Myelo… Myelodysplastic… Preleukemia Acute Myeloid L… Therapy-related… de Novo Acute M… | No objective response was observed at the first step. The treatment was considered ineffective,
with a complete clinical trial suspension. - | |||
| NCT01335997 2011-001007-12 Details | 2019-02-06 Interventional | 3 | 1139 | Niacin Niacinamide Nicotinic Acids Simvastatin Dyslipidemias Hypercholestero… Mixed Dyslipide… Primary Hyperch… | Business Reasons Study was terminated for business reasons. | |||
| NCT01301391 Details | 2019-02-06 Interventional | 2 | 30 | Maleic acid Thymoma Thymus Neoplasm… Malignant Thymo… | For the last patient still on treated nominal therapeutic use of the Milciclib was approved at
INT Milano. - | |||
| NCT01011439 2009-014338-79 Details | 2019-02-06 Interventional | 2 | 72 | Maleic acid Carcinoma Thymoma Thymic Carcinom… | For the 2 last patients still on treated nominal therapeutic use of the Milciclib was approved
at INT Milano. - | |||
| NCT02533336 Details | 2019-02-05 Interventional | 3 | 4917 | Abamectin Malaria | futility ground - | |||
| NCT02393378 2014-002945-23 Details | 2019-02-05 Interventional | 2 | 7 | Adalimumab Folic Acid Methotrexate Arthritis Arthritis, Rheu… Rheumatoid Arth… | Strategic decision - to understand data from psoriasis study - NCT02129777 and wait for results
of formal proof of concept study - NCT02379091. - | |||
| NCT02044510 Details | 2019-02-05 Interventional | 2/3 | 32 | Mirabegron Urinary Bladder… | Slow recruitment and small observed effect size - | |||
| NCT01115803 Details | 2019-02-05 Interventional | 1 | 29 | Erlotinib Hydro… Everolimus Carcinoma Carcinoma, Non-… Carcinoma, Rena… Neoplasm Metast… Neuroendocrine … Carcinoma, Non-… Metastases, Neo… Renal Cell Carc… | Primary objective has been met; safety and pharmacokinetics have been characterized. Study terminated early. Dose confirmation, Part B, was not initiated. | |||
| NCT01025882 Details | 2019-02-05 Interventional | 1 | 5 | Gemcitabine Pancreatic Neop… Pancreatic Canc… | DSMC closed due to patient deaths - | |||
| NCT00080119 Details | 2019-02-05 Interventional | 2/3 | [2 Refs] | 1354 | Isoniazid Sulfamethoxazol… Trimethoprim Infections Pneumonia, Pneu… Tuberculosis HIV Infection Pneumocystis Ji… | Data Safety Monitoring Board (DSMB) recommended stopping study due to futility DSMB recommended stopping study due to futility: "no compelling reason to enroll additional infants" or "to continue to treat participants with the blinded study medication". Week 192 analyses not done as <4% (26%) of HIVpos (HIVneg) reached wk 192 | ||
| NCT03717038 2018-003187-31 Details | 2019-02-04 Interventional | 3 | 0 | Trifluridine Carcinoma Colorectal Neop… Colorectal Canc… Metastatic Colo… | Study was withdrawn due to administrative reasons - |